Jakson kuvaus
When Abivax released stunning phase 3 results for ulcerative colitis, its 600% stock price surge froze Euronext for 45 minutes.
Philip meets Abivax CEO Marc de Garidel in Vienna, Austria, to go behind the scenes of a remarkable biotech turnaround.
Marc discusses the processes involved in executing the phase 3 trial that beat even Abivaxâs own phase 2 data. He also talks about Franceâs biotech ecosystem and the importance of having the right team.
âïž ABOUT THE SPEAKER
Marc de Garidel joined Abivax as CEO in 2023. Prior to this, he led two biotech companies through billion-dollar exitsâŠ
Sivusto: podcasters.spotify.com

